Quick Answer
Whitehawk Therapeutics, Inc. reported Cash and Equivalents of $37.57 million for fiscal year 2025.
Whitehawk Therapeutics, Inc. Cash and Equivalents — Annual History
| Fiscal Year | Cash and Equivalents | YoY Change |
|---|---|---|
| 2025 | $37.57M | +31.0% |
| 2024 | $28.67M | -54.4% |
| 2023 | $62.89M | +61.2% |
| 2022 | $39.02M | -73.8% |
| 2021 | $148.99M | +3244.3% |
| 2020 | $4.46M | -88.4% |
| 2019 | $38.52M | -38.5% |
| 2018 | $62.61M | +209.0% |
| 2017 | $20.26M | +1158.9% |
| 2016 | $1.61M | -68.7% |
| 2015 | $5.14M | +81944.8% |
| 2015 | $6.3K | +19.1% |
| 2014 | $5.3K | -16.2% |
| 2013 | $6.3K | +36.4% |
| 2012 | $4.6K | -14.5% |
| 2012 | $5.4K | +30.7% |
| 2011 | $4.1K | -32.7% |
| 2011 | $6.1K | -77.2% |
| 2010 | $26.9K | +141.4% |
| 2009 | $11.1K | — |
| 2007 | $0.00 | — |
| 2007 | $0.00 | — |
Quarterly Cash and Equivalents
| Quarter Ending | Cash and Equivalents | YoY | QoQ |
|---|---|---|---|
| September 30, 2025 | $37.93M | +24.2% | -73.8% |
| June 30, 2025 | $144.94M | +252.3% | -36.3% |
| March 31, 2025 | $227.57M | +323.1% | +693.8% |
| December 31, 2024 | $28.67M | -54.4% | -6.1% |
| September 30, 2024 | $30.54M | -55.6% | -25.8% |
| June 30, 2024 | $41.14M | -39.6% | -23.5% |
| March 31, 2024 | $53.78M | +58.0% | -14.5% |
| December 31, 2023 | $62.89M | +61.2% | -8.6% |
- Whitehawk Therapeutics, Inc. showed an increase of +31.0% in Cash and Equivalents compared to the prior fiscal year.
- The most recent figure is from Whitehawk Therapeutics, Inc.’s fiscal year 2025 report (Form 10-K), filed with the SEC on March 12, 2026.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: